Minaris Fortifies Philly Hub to Streamline Cell & Gene Therapy Production

PHILADELPHIA, PA – June 18, 2026 – Minaris, a global contract development and manufacturing organization (CDMO) for the cell and gene therapy (CGT) industry, today announced a significant enhancement of its GMP cell banking suites at its Philadelphia facility. The move integrates critical manufacturing and testing services under one roof, a strategic decision aimed at simplifying the complex and high-stakes journey of bringing advanced therapies from the laboratory to patients.

A Strategic Leap in a Burgeoning Market

The CGT sector is experiencing explosive growth, with the global CDMO market projected to surge from approximately $6.4 billion in 2024 to over $75 billion by 2034, expanding at a compound annual growth rate of nearly 28%. In this fiercely competitive landscape, where established players like Lonza and Catalent also vie for dominance, the ability to offer integrated, end-to-end solutions has become a key differentiator.

Minaris' enhancement is a direct response to this market demand. Drug developers, particularly smaller biotechs, are increasingly seeking “one-stop-shop” partners to navigate the logistical, regulatory, and financial hurdles of CGT development. By consolidating GMP cell banking with comprehensive characterization and biosafety testing—including for sterility, mycoplasma, and viral safety—the company aims to eliminate the delays and communication gaps that often arise from managing multiple vendors.

"Cell banking is one of the most important steps in biologics and advanced therapy development, and our clients require a partner that delivers quality, predictability, and regulatory assurance from the outset," said Dr. Ilya Koltover, President of Minaris Advanced Testing. "Our goal is to make cell banking simpler by bringing dedicated GMP infrastructure, integrated testing and cell line characterization, regular program updates, and expert teams with decades of experience together under one roof."

This integrated model, which provides clients with daily manufacturing updates and coordinated project management, is designed to reduce complexity and accelerate timelines, offering a crucial advantage in the race to bring life-changing therapies to market.

Mastering the Global Regulatory Gauntlet

Bringing a cell or gene therapy to market requires navigating a labyrinth of stringent international regulations. A primary challenge is compliance with standards like the revised EU GMP Annex 1, which came into full effect in 2023 and dictates the manufacture of sterile medicinal products. Annex 1 mandates a holistic Contamination Control Strategy (CCS), demanding rigorous facility design, continuous environmental monitoring, and meticulous quality risk management.

Minaris' upgraded Philadelphia suites were engineered to meet these exacting requirements head-on. The specialized clean rooms feature multiple dedicated suites with controlled personnel and material flows to prevent cross-contamination. Critically, they include ISO 5 (Grade A) critical zones—areas of highest air purity for aseptic processing—housed within ISO 7 (Grade B) background cleanrooms, a design that directly aligns with global standards for sterile manufacturing.

The facility also boasts modernized environmental monitoring systems and enhanced quality oversight, strengthening contamination control and ensuring the integrity of the Master and Working Cell Banks that form the foundation of any therapeutic program.

"Operational rigor is at the core of our GMP environments," stated Dr. Orla Cloak, Chief Executive Officer of Minaris. "These enhanced suites improve efficiency and predictability while maintaining the rigorous standards required for GMP production. With integrated characterization and daily visibility into program progress, we're helping clients reach key milestones on the path to regulatory-ready cell banks."

This commitment to regulatory adherence provides therapy developers with the assurance that their foundational materials are compliant from the very beginning, de-risking the path to clinical trials and commercialization.

Cementing Philadelphia's 'Cellicon Valley' Status

This investment does more than just enhance a single company's capabilities; it further solidifies Philadelphia's reputation as a global epicenter for cell and gene therapy innovation, often dubbed 'Cellicon Valley'. The Minaris campus, a cornerstone of its testing network spanning 140,000 square feet, is a significant part of the region's biotech infrastructure.

By centralizing advanced cell banking and testing services in the city, Minaris not only strengthens its own offering but also contributes to the robust ecosystem that attracts talent, capital, and a critical mass of scientific expertise. For biotech companies in the region and beyond, the presence of such a high-caliber, integrated facility reduces logistical hurdles and provides local access to world-class manufacturing and testing support. This symbiotic relationship between major industry players and the regional cluster fuels a cycle of growth, innovation, and economic development, making Philadelphia an increasingly attractive location for CGT startups and established pharmaceutical companies alike.

An Integrated Vision, A Global Footprint

The Philadelphia enhancement is not an isolated event but the latest move in a deliberate, long-term growth strategy for Minaris. The company itself, in its current form, is a relatively new powerhouse, formed in May 2025 after investment firm Altaris acquired and combined Minaris Regenerative Medicine with the U.S. and U.K. operations of WuXi Advanced Therapies. This move created a global CDMO with a massive footprint of over 730,000 square feet and deep expertise spanning decades.

This strategic vision is evident in a series of recent expansions. In August 2025, the company opened a new state-of-the-art GMP manufacturing facility in Munich, Germany, bolstering its European presence. In 2024, its Allendale, New Jersey site received FDA approval for commercial production and completed its first commercial run. Even within its Philadelphia campus, the company upgraded its Viral Clearance laboratory in January 2026 to increase capacity and efficiency.

Together, these investments paint a clear picture of a company aggressively expanding its capabilities and global reach. By integrating its services and harmonizing its quality systems across sites in North America, Europe, and Asia, Minaris is positioning itself as a single, reliable partner capable of guiding innovators from the earliest stages of development all the way through to commercial supply, helping to bring more transformative therapies to more patients worldwide.